⭐ Start off 2025 with a powerful boost to your portfolio: January’s freshest AI-picked stocksUnlock stocks

Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock

Published 11/14/2024, 06:11 AM
Updated 11/14/2024, 06:12 AM
THAR
-

In a recent transaction reported to the Securities and Exchange Commission, Appajosyula Sireesh, Chief Operating Officer of Tharimmune, Inc. (NASDAQ:THAR), acquired 5,000 shares of common stock at a price of $2.0192 per share. This purchase, totaling approximately $10,096, increases Sireesh's direct ownership to 10,758 shares.

In addition to his direct holdings, Sireesh also holds shares indirectly through Highpoint Pharmaceuticals, LLC and Channel BioConsulting LLC. Specifically, Highpoint Pharmaceuticals holds 2,593 shares, while Channel BioConsulting holds 21 shares. As the managing member of both entities, Sireesh has the authority to vote and dispose of these securities.

In other recent news, Tharimmune, Inc. has made significant strides in its clinical trials and strategic partnerships. The biotech firm has secured a European patent for its biodegradable polymeric nanoparticles technology, a development anticipated to enhance cancer therapies. The company has also received encouraging feedback from the European Medicines Agency (EMA) on its Phase 2 clinical trial plans for TH104, a drug candidate for pruritus in primary biliary cholangitis (PBC), with topline data expected in 2025.

Tharimmune's recent Phase 1 data for TH104 indicates potential for rapid symptomatic relief in patients with chronic liver disease. Positive results from this trial have paved the way for a Phase 2 multiple-ascending dose trial. Additionally, Tharimmune has entered into an exclusive licensing agreement with Intract Pharma for a novel oral delivery platform for anti-inflammatory treatments, which could accelerate the oral anti-TNFα antibody into clinical trials.

These recent developments underscore Tharimmune's ongoing efforts to expand its immunology focus and offer more accessible treatment options. The company is also exploring strategic partnerships to further refine the targeting capabilities of its platform and continues to develop its portfolio, which includes early-stage multi-specific biologics for solid tumors.

InvestingPro Insights

The recent insider purchase by Tharimmune's COO comes at a time when the company's stock has faced significant challenges. According to InvestingPro data, Tharimmune's shares have experienced a steep decline, with a 96.87% drop in the past year and a 61.37% fall over the last six months. This aligns with an InvestingPro Tip indicating that the stock "has taken a big hit over the last six months."

Despite these setbacks, the company maintains a strong liquidity position. An InvestingPro Tip highlights that Tharimmune "holds more cash than debt on its balance sheet" and that its "liquid assets exceed short term obligations." This financial stability could provide some reassurance to investors in light of the recent stock performance.

It's worth noting that analysts are cautious about the company's near-term profitability. An InvestingPro Tip suggests that analysts "do not anticipate the company will be profitable this year." This is further supported by the negative P/E ratio of -0.23 for the last twelve months as of Q3 2024.

For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Tharimmune, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.